Summary & Overview
HCPCS Level II J0630: Injection, Calcitonin Salmon, up to 400 Units
HCPCS Level II code J0630 denotes an injectable formulation of salmon calcitonin (up to 400 units) administered for clinical indications that require calcitonin therapy. Nationally, this code matters because it captures utilization and billing for a specialty injectable medication used in niche musculoskeletal and metabolic bone disorders, affecting coverage, prior authorization practices, and pharmacy-administered service lines.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding context, payer coverage patterns, and the clinical setting tied to J0630.
This publication provides practical benchmarks and policy context: typical sites of service for administration, payer inclusion in national coverage landscapes, and factors that influence billing and claims processing for this injectable therapy. The summary also outlines clinical context for calcitonin salmon use and what to expect in service lines that bill for injectable agents. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0630 describes an injection of calcitonin salmon, up to 400 units. This code represents administration of a synthetic or recombinant form of salmon calcitonin used for conditions where calcitonin therapy is indicated.
Service Type: Injectable medication administration
Typical Site of Service: Outpatient clinic, physician office, or other ambulatory setting where injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an older adult presenting to an outpatient infusion center or a physician office for management of osteoporosis or acute osteoporotic vertebral compression fractures. The clinician prescribes J0630 (injection, calcitonin salmon, up to 400 units) for short-term analgesia of acute vertebral compression fracture pain or as adjunctive therapy for osteoporosis when indicated. The typical clinical workflow: the patient arrives to the clinic, vital signs and allergy screen are completed, informed consent for medication administration is obtained, and a nurse or licensed provider prepares the medication per manufacturer and facility protocols. The medication is administered either intranasally (if using nasal formulation alternatives) or by subcutaneous/intramuscular injection depending on formulation and ordering instructions; documentation includes medication name J0630, units administered, lot number, route, site, and supervising clinician. Monitoring for immediate adverse reactions (allergic response, nausea, flushing) occurs for an observation period after administration. Billing includes the HCPCS Level II code J0630 for the drug supply; separate billing for administration may be required using applicable CPT or administration codes and appropriate modifiers to indicate service circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|